Related references
Note: Only part of the references are listed.Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata
V. Nagappan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Fungal echinocandin resistance
Louise A. Walker et al.
FUNGAL GENETICS AND BIOLOGY (2010)
Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers
Anthony M. Nicasio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-D-Glucan Levels
Luis Ostrosky-Zeichner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis
Vidmantas Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Anidulafungin Is Fungicidal and Exerts a Variety of Postantifungal Effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates
Katherine T. Nguyen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
Robert F. Betts et al.
CLINICAL INFECTIOUS DISEASES (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
W. W. Hope et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections
Kazuro Ikawa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
In vitro activity of anidulafungin against Candida albicans biofilms
Melissa J. Jacobson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans
Nicolas Venisse et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.
Carolina Serena et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C-glabrata in a neutropenic murine candidiasis model
D. R. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Immunopharmacology of modern antifungals
R. Ben-Ami et al.
CLINICAL INFECTIOUS DISEASES (2008)
Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice
L. K. Najvar et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Significant differences in drug susceptibility among species in the Candida parapsilosis group
Eveline van Asbeck et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis
Russell E. Lewis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Gabriela E. Brzankalski et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth
Estelle Cateau et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin:: Analysis and proposal for interpretive MIC breakpoints
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae
Gregory A. Lamaris et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
D. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C-dubliniensis
M. Fleischhacker et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2008)
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia
Charalampos Antachopoulos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
In vitro activity of micafungin combined with itraconazole against Candida spp.
Marcal Marine et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)
Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species
Analy S. Melo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds
A. Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Anidulafungin versus fluconazole for invasive candidiasis
Annette C. Reboli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Resistance to echinocandin-class antifungal drugs
David S. Perlin
DRUG RESISTANCE UPDATES (2007)
Paradoxical effect of echinocandins across Candida species in vitro:: Evidence for echinocandin-specific and Candida species-related differences
Georgios Chamilos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Ruediger Kuse et al.
LANCET (2007)
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase
Jennifer Nielsen Kahn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals
Hyun Woo Choi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species
Charalampos Antachopoulos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans
Carol A. Munro et al.
MOLECULAR MICROBIOLOGY (2007)
Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis
M. A. Ghannoum et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections
Marc Seidler et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species
Elizabeth M. O'Shaughnessy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Determination of MICs of aminocandin for Candida spp. and filamentous fungi
N. Isham et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Comparison of antifungal treatments for murine fusariosis
Brad Spellberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
David W. Denning et al.
JOURNAL OF INFECTION (2006)
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility
Jason Cota et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Echinocandins in the management of invasive fungal infections, part 2
Michele I. Morris et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Echinocandins in the management of invasive fungal infections, part 1
Michele I. Morris et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model
Jennifer A. Shuford et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Escape of Candida from caspofungin inhibition at concentrations above the MIC (Paradoxical effect) accomplished by increased cell wall chitin;: Evidence for β-1,6-glucan synthesis inhibition by caspofungin
David A. Stevens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis
RR Klont et al.
CLINICAL INFECTIOUS DISEASES (2006)
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy
Morgan Hakki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
A drug-sensitive genetic network masks fungi from the immune system
Robert T. Wheeler et al.
PLOS PATHOGENS (2006)
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
M Laverdière et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
M Krogh-Madsen et al.
CLINICAL INFECTIOUS DISEASES (2006)
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis
KV Clemons et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The echinocandins: Comparison of their pharmacokinetics, pharmacodynamics and clinical applications
Claudia Wagner et al.
PHARMACOLOGY (2006)
Attenuation of the activity of caspofungin at high concentrations against Candida albicans:: Possible role of cell wall integrity and calcineurin pathways
NP Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity
A Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani
K Heyn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Micafungin in combination with voriconazole in Aspergillus species:: a pharmacodynamic approach for detection of combined antifungal activity in vitro
RE Lewis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
L Ostrosky-Zeichner et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms
C Cocuaud et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment outcome
N Kartsonis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusatium spp.
A Philip et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Studies of the paradoxical effect of caspofungin at high drug concentrations
DA Stevens et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus
M Cuenca-Estrella et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Multiechinocandin- and multiazole-resistant Candida parapsilosis solates serially obtained during therapy for prosthetic valve endocarditis
V Moudgal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Caspofungin inhibits rhizopus oryzae 1,3-β-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis
AS Ibrahim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: Case report and review of literature
R Pelletier et al.
MEDICAL MYCOLOGY (2005)
A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan
S Kohno et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2004)
Caspofungin resistance in Candida albicans:: Correlating clinical outcome with laboratory susceptibility testing of three is genic isolates serially obtained from a patient with progressive candida esophagitis
S Hernandez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus
JH Choi et al.
MICROBES AND INFECTION (2004)
Combination antifungal therapy
MD Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus
E Dannaoui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans
EK Manavathu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients
N de Wet et al.
CLINICAL INFECTIOUS DISEASES (2004)
Paradoxical effect of caspofungin:: Reduced activity against Candida albicans at high drug concentrations
DA Stevens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent
K Pettengell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
FC Odds et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Toward more effective antifungal therapy: the prospects of combination therapy
DP Kontoyiannis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
DS Krause et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies
G Di Bonaventura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity
NP Wiederhold et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis
RM Prabhu et al.
CLINICAL INFECTIOUS DISEASES (2004)
Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far
DP Kontoyiannis et al.
DRUG RESISTANCE UPDATES (2003)
Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis
JR Graybill et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin
V Petraitis et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: Comparison of yeast-like and mycelial forms
T Nakai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Efficacy of micafungin alone or in combination against systemic murine aspergillosis
JC Luque et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
In vitro activity of micafungin (FK-463) against Candida spp.:: Microdilution, time-kill, and postantifungal-effect studies
EJ Ernst et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies
G Ramage et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro
JC Bowman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
S Perea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis
WR Kirkpatrick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits
V Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal susceptibility of Candida biofilms:: Unique efficacy of amphotericin B lipid formulations and echinocandins
DM Kuhn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods
EE Roling et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2002)
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
S Arikan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
AH Groll et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus
T Chiller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2001)
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
J Roberts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
EJ Ernst et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
